Drug intelligence / Profile preview

BIBF0775

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Small Molecules

Overview

BIBF0775: sourced facts only. name: "Guided by an X-ray structure of lead compound 5 (BIBF0775) soaked into the kinase domain of TGFβRI" [1] target: "Guided by an X-ray structure of lead compound 5 (BIBF0775) soaked into the kinase domain of TGFβRI" [1] developer: "Biberach, Department of Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co KG," [1] modality: "Indolinones substituted in position 6 were identified as a new chemotype inhibiting TGFβRI concomitant with a low cross-reactivity among the human kinome." [1]

Targets

TGFBR1

Beyond the preview

Go deeper on BIBF0775.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIBF0775.